Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;4(2):333-347.
doi: 10.1007/s40744-017-0064-4. Epub 2017 May 15.

Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis

Katelynn M Wilton  1 , Eric L Matteson  2
Affiliations
Review

Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis

Katelynn M Wilton et al. Rheumatol Ther. 2017 Dec.

Abstract

Traditional and biologic disease-modifying antirheumatic drugs (DMARDs) are effective medications for the management of rheumatoid arthritis (RA). However, the effects of these medications on immune function raises concern that they may increase long-term cancer risk. The baseline risk for some cancers appears to differ in patients with RA compared to the general population, with the former having an increased risk of lymphoma, lung cancer and renal cancer, but a decreased risk of colorectal and breast cancer. Some DMARDs appear to increase the rate of specific cancer types (such as bladder cancer with cyclophosphamide), but few appear to increase the overall cancer risk. Studying the link between lymphoma and disease severity in RA is complicated because patients with persistently active disease are at increased risk for lymphoma, and disease severity correlates with more intense use of immunosuppressive medications. Overall, cancer risk in patients with RA is slightly above that of the general population, with the increased risk likely secondary to an increased risk of lymphomas in those with high disease activity. Risk mitigation includes management of RA disease activity as well as age- and sex-appropriate cancer screening.

Keywords: Cancer; Comorbidity; Inflammation; Malignancy; Rheumatoid arthritis.

PubMed Disclaimer

References

    1. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;15(17):212. - PMC - PubMed
    1. Raheel S, Crowson CS, Wright K, Matteson EL. Risk of malignant neoplasm in patients with incident rheumatoid arthritis 1980–2007 in relation to a comparator cohort: a population-based study. Int J Rheumatol. 2016;2016:4609486. - PMC - PubMed
    1. Hashimoto A, Chiba N, Tsuno H, Komiya A, Furukawa H, Matsui T, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42(4):564–571. - PubMed
    1. Huang WK, Chiou MJ, Kuo CF, Lin YC, Yu KH, See LC. No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan. Rheumatol Int. 2014;34(10):1379–1386. - PubMed
    1. Andersen CL, Lindegaard H, Vestergaard H, Siersma VD, Hasselbalch HC, de Fine Olivarius N, et al. Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting. PLoS ONE. 2014;9(6):e99388. - PMC - PubMed